FiercePharmaAsia—Gilead remdesivir's copy; Enhertu's early launch; Tecentriq's China nod

14th February 2020 Uncategorised 0

A Chinese drugmaker has started mass producing a generic to Gilead’s remdesivir without any licensing agreement. HER2-targeting Enhertu has got off to a fast start, Daiichi Sankyo U.S. chief said. Roche’s Tecentriq won approval in China in first-line small cell lung cancer. And more.

More: FiercePharmaAsia—Gilead remdesivir's copy; Enhertu's early launch; Tecentriq's China nod
Source: fierce